NHS National Framework for Tafamidis
NHS England is establishing a national framework to supply tafamidis (a transthyretin stabiliser for cardiac amyloidosis) to the NHS over 14 months from April 2027, with optional extensions up to 24 months total.
- Closed31 August 2026
- Value£65m
- BuyerNHS England
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a pharmaceutical supplier licensed to distribute tafamidis in the UK and can meet NHS volume and compliance requirements
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Mercury Pharmaceuticals Limited has won similar NHS pharmaceutical framework agreements in 2025. Inferred from prior awards to this buyer, not confirmed.